1. Home
  2. ETNB

ETNB

89bio Inc.

Logo 89bio Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Founded: 2018 Country:
United States
United States
Employees: N/A City: SAN FRANCISCO
Market Cap: 864.6M IPO Year: 2019
Target Price: $29.00 AVG Volume (30 days): 1.3M
Analyst Decision: Strong Buy Number of Analysts: 8
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.00 EPS Growth: N/A
52 Week Low/High: $6.58 - $22.93 Next Earning Date: 05-02-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 133.30%

Share on Social Networks:

Stock Insider Trading Activity of 89bio Inc. (ETNB)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
PALEKAR ROHAN ETNB Chief Executive Officer Feb 26 '24 Sell $10.76 4,477 $48,172.52 486,889 SEC Form 4
PALEKAR ROHAN ETNB Chief Executive Officer Dec 29 '23 Sell $11.20 50,000 $560,000.00 301,225 SEC Form 4